164 related articles for article (PubMed ID: 28571549)
1. Nanoemulsion-Based Transdermal Drug Delivery System for the Treatment of Tuberculosis.
Wais M; Aqil M; Goswami P; Agnihotri J; Nadeem S
Recent Pat Antiinfect Drug Discov; 2017; 12(2):107-119. PubMed ID: 28571549
[TBL] [Abstract][Full Text] [Related]
2. Nanoemulsion for the Effective Treatment and Management of Anti-tubercular Drug Therapy.
Beg S; Saini S; Imam SS; Rahman M; Swain S; Hasnain MS
Recent Pat Antiinfect Drug Discov; 2017; 12(2):85-94. PubMed ID: 28480833
[TBL] [Abstract][Full Text] [Related]
3. Novel Approach for Transdermal Delivery of Rifampicin to Induce Synergistic Antimycobacterial Effects Against Cutaneous and Systemic Tuberculosis Using a Cationic Nanoemulsion Gel.
Hussain A; Altamimi MA; Alshehri S; Imam SS; Shakeel F; Singh SK
Int J Nanomedicine; 2020; 15():1073-1094. PubMed ID: 32103956
[TBL] [Abstract][Full Text] [Related]
4. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology based drug delivery system(s) for the management of tuberculosis.
Pandey R; Khuller GK
Indian J Exp Biol; 2006 May; 44(5):357-66. PubMed ID: 16708887
[TBL] [Abstract][Full Text] [Related]
6. Nano-carriers for the Treatment of Tuberculosis.
Gilani SJ; Ameeduzzafar ; Jafar M; Shakil K; Imam SS
Recent Pat Antiinfect Drug Discov; 2017; 12(2):95-106. PubMed ID: 28595544
[TBL] [Abstract][Full Text] [Related]
7. Omega 3 fatty acid-enriched nanoemulsion of thiocolchicoside for transdermal delivery: formulation, characterization and absorption studies.
Kumar D; Ali J; Baboota S
Drug Deliv; 2016; 23(2):591-600. PubMed ID: 24892633
[TBL] [Abstract][Full Text] [Related]
8. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis.
Sharma A; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2004 Dec; 24(6):599-604. PubMed ID: 15555884
[TBL] [Abstract][Full Text] [Related]
10. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.
Gelperina S; Kisich K; Iseman MD; Heifets L
Am J Respir Crit Care Med; 2005 Dec; 172(12):1487-90. PubMed ID: 16151040
[TBL] [Abstract][Full Text] [Related]
11. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
Singh J; Garg T; Rath G; Goyal AK
Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
[TBL] [Abstract][Full Text] [Related]
12. Transdermal delivery of anticancer drug caffeine from water-in-oil nanoemulsions.
Shakeel F; Ramadan W
Colloids Surf B Biointerfaces; 2010 Jan; 75(1):356-62. PubMed ID: 19783127
[TBL] [Abstract][Full Text] [Related]
13. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: Formulation development, stability issues, basic considerations and applications.
Rai VK; Mishra N; Yadav KS; Yadav NP
J Control Release; 2018 Jan; 270():203-225. PubMed ID: 29199062
[TBL] [Abstract][Full Text] [Related]
14. Nanoemulsion system for the transdermal delivery of a poorly soluble cardiovascular drug.
Dixit N; Kohli K; Baboota S
PDA J Pharm Sci Technol; 2008; 62(1):46-55. PubMed ID: 18402367
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
Dutt M; Khuller GK
Antimicrob Agents Chemother; 2001 Jan; 45(1):363-6. PubMed ID: 11121000
[TBL] [Abstract][Full Text] [Related]
16. Nanostructured drug delivery for better management of tuberculosis.
Kaur IP; Singh H
J Control Release; 2014 Jun; 184():36-50. PubMed ID: 24732260
[TBL] [Abstract][Full Text] [Related]
17. Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications.
Pandey R; Sharma S; Khuller GK
Indian J Exp Biol; 2006 Jun; 44(6):459-67. PubMed ID: 16784116
[TBL] [Abstract][Full Text] [Related]
18. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis.
Kaur M; Garg T; Rath G; Goyal AK
Crit Rev Ther Drug Carrier Syst; 2014; 31(1):49-88. PubMed ID: 24579767
[TBL] [Abstract][Full Text] [Related]
19. Nanostructured Therapeutic Carriers for Tuberculosis Treatment: Approaches & Challenges.
Ullah Z; Athar MT; Samad A
Recent Pat Antiinfect Drug Discov; 2017; 12(2):128-137. PubMed ID: 28990537
[TBL] [Abstract][Full Text] [Related]
20. Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention.
Nabi B; Rehman S; Aggarwal S; Baboota S; Ali J
Drug Deliv Transl Res; 2020 Aug; 10(4):1111-1121. PubMed ID: 32418158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
